Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
62 hedge funds and large institutions have $56.5M invested in Mirati Therapeutics, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 14 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 19
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 69 → 62 (-7)
30% less capital invested
Capital invested by funds: $80.1M → $56.5M (-$23.7M)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
98% less call options, than puts
Call options by funds: $2K | Put options by funds: $85K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.5M |
| 2 |
Millennium Management
New York
|
+$462K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$371K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$277K |
| 5 |
D.E. Shaw & Co
New York
|
+$213K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$1.29M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.24M |
| 3 |
BC
Broadfin Capital
New York
|
-$947K |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$826K |
| 5 |
Renaissance Technologies
New York
|
-$706K |
MRTX Hedge Fund Activity: Q4 2016 in Review
62 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q4 2016, worth a combined $56.5M — down 30% from $80.1M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of MRTX and 7 opened new positions — a net loss of 7 holders — while 19 trimmed existing stakes and 21 added.
The largest buyer was Great Point Partners, adding an estimated $3.5M. The largest seller was Franklin Resources, cutting an estimated $1.29M.
- 62 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q4 2016, down from 69 in Q3 2016.
- Funds reported $56.5M of Mirati Therapeutics, Inc. Common Stock stock for Q4 2016, down 30% quarter-over-quarter.
- 7 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q4 2016 and 14 closed out, a net change of -7 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q4 2016 was Great Point Partners, an estimated $3.5M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q4 2016 was Franklin Resources, an estimated $1.29M sold.
Based on aggregated 13F filings for Q4 2016.